Anika Therapeutics, Inc. (ANIK) Spending and interest coverage
- R&D / revenue · 12 months: Value 22.75%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 10.90%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 22.75% | Research and development expense / revenue. Period ending 2026-06-30. $27.45M ÷ $120.65M × 100 ≈ 22.75% |
| Stock-based compensation / revenue · 12 months | 10.90% | Share-based compensation / revenue. Period ending 2026-06-30. $13.15M ÷ $120.65M × 100 ≈ 10.90% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 27.45M USD | Research and Development Expense |
| Revenue | 120.65M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 13.15M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -5.12M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $27.45M | $120.65M | $13.15M | $-5.12M | (m) | 22.75% | 10.90% | (m) | (m) |
| 2026-03-31 | $26.42M | $116.26M | $13.86M | $-12.26M | (m) | 22.73% | 11.92% | (m) | (m) |
| 2025-12-31 | $25.77M | $112.82M | $10.08M | $-11.05M | (m) | 22.84% | 8.94% | (m) | (m) |
| 2025-09-30 | $25.82M | $112.81M | $9.88M | $-12.40M | (m) | 22.89% | 8.76% | (m) | (m) |
| 2025-06-30 | $24.82M | $114.55M | $11.06M | $-9.25M | (m) | 21.67% | 9.66% | (m) | (m) |
| 2025-03-31 | $25.19M | $117.05M | $12.40M | $-6.88M | (m) | 21.52% | 10.60% | (m) | (m) |
| 2024-12-31 | $25.54M | $119.91M | $13.13M | $-5.10M | (m) | 21.30% | 10.95% | (m) | (m) |
| 2024-09-30 | $30.39M | $164.17M | $14.69M | $-96.70M | (m) | 18.51% | 8.95% | (m) | (m) |
| 2024-06-30 | $30.94M | $166.88M | $14.86M | $-76.36M | (m) | 18.54% | 8.90% | (m) | (m) |
| 2024-03-31 | $32.45M | $169.26M | $15.12M | $-80.15M | (m) | 19.17% | 8.93% | (m) | (m) |
| 2023-12-31 | $32.69M | $166.66M | $15.24M | $-87.64M | (m) | 19.61% | 9.15% | (m) | (m) |
| 2023-09-30 | $32.85M | $163.31M | $15.24M | $-30.52M | (m) | 20.12% | 9.33% | (m) | (m) |
| 2023-06-30 | $32.36M | $162.11M | $15.56M | $-28.65M | (m) | 19.96% | 9.60% | (m) | (m) |
| 2023-03-31 | $30.43M | $157.47M | $15.49M | $-28.40M | (m) | 19.32% | 9.84% | (m) | (m) |
| 2022-12-31 | $28.18M | $156.24M | $14.31M | $-19.40M | (m) | 18.04% | 9.16% | (m) | (m) |
| 2022-09-30 | $26.43M | $152.44M | $13.67M | $-21.86M | (m) | 17.34% | 8.97% | (m) | (m) |
| 2022-06-30 | $26.80M | $151.71M | $12.65M | $-14.76M | (m) | 17.67% | 8.34% | (m) | (m) |
| 2022-03-31 | $27.12M | $150.19M | $11.37M | $-2.20M | (m) | 18.06% | 7.57% | (m) | (m) |
| 2021-12-31 | $27.33M | $147.79M | $11.09M | $2.62M | (m) | 18.49% | 7.50% | (m) | (m) |
| 2021-09-30 | $28.96M | $144.66M | $9.35M | $-6.21M | (m) | 20.02% | 6.46% | (m) | (m) |
| 2021-06-30 | $26.50M | $136.82M | $8.41M | $-15.44M | (m) | 19.37% | 6.15% | (m) | (m) |
| 2021-03-31 | $23.74M | $129.35M | $7.85M | $-34.16M | (m) | 18.35% | 6.07% | (m) | (m) |
| 2020-12-31 | $23.43M | $130.46M | $5.39M | $-28.32M | (m) | 17.96% | 4.13% | (m) | (m) |
| 2020-09-30 | $19.88M | $127.54M | $5.90M | $-5.57M | (m) | 15.59% | 4.63% | (m) | (m) |
| 2020-06-30 | $18.82M | $125.54M | $5.29M | $14.41M | (m) | 14.99% | 4.21% | (m) | (m) |
| 2020-03-31 | $18.46M | $125.28M | $4.49M | $35.86M | (m) | 14.73% | 3.59% | (m) | (m) |
| 2019-12-31 | $16.66M | $114.61M | $6.09M | $34.25M | (m) | 14.54% | 5.31% | (m) | (m) |
| 2019-09-30 | $16.64M | $111.79M | $5.12M | $39.21M | (m) | 14.89% | 4.58% | (m) | (m) |
| 2019-06-30 | $16.72M | $108.88M | $4.99M | $35.73M | (m) | 15.35% | 4.58% | (m) | (m) |
| 2019-03-31 | $17.29M | $109.01M | $4.87M | $35.06M | (m) | 15.86% | 4.46% | (m) | (m) |
| 2018-12-31 | $18.19M | $105.56M | $11.05M | $21.75M | (m) | 17.23% | 10.46% | (m) | (m) |
| 2018-09-30 | $18.39M | (m) | $11.93M | $21.71M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $20.00M | (m) | $12.23M | $23.41M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $19.72M | (m) | $12.19M | $29.89M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $18.79M | $113.42M | $5.81M | $45.73M | (m) | 16.56% | 5.12% | (m) | (m) |
| 2017-09-30 | $17.48M | $112.76M | $5.06M | $48.74M | (m) | 15.50% | 4.48% | (m) | (m) |
| 2017-06-30 | $14.46M | $111.36M | $4.38M | $52.16M | (m) | 12.98% | 3.93% | (m) | (m) |
| 2017-03-31 | $12.80M | $104.48M | $3.76M | $47.90M | (m) | 12.25% | 3.60% | (m) | (m) |
| 2016-12-31 | $10.73M | $103.38M | $3.39M | $50.61M | (m) | 10.38% | 3.28% | (m) | (m) |
| 2016-09-30 | $10.79M | $105.55M | $2.94M | $54.93M | (m) | 10.22% | 2.78% | (m) | (m) |
| 2016-06-30 | $10.03M | $103.44M | $2.64M | $54.38M | (m) | 9.69% | 2.55% | (m) | (m) |
| 2016-03-31 | $9.05M | $99.76M | $2.49M | $53.34M | (m) | 9.07% | 2.49% | (m) | (m) |
| 2015-12-31 | $8.99M | $93.00M | $2.23M | $48.13M | (m) | 9.66% | 2.39% | (m) | (m) |
| 2015-09-30 | $7.96M | $85.36M | $1.97M | $43.16M | (m) | 9.32% | 2.31% | (m) | (m) |
| 2015-06-30 | $7.89M | $83.73M | $1.87M | $40.31M | (m) | 9.43% | 2.23% | (m) | (m) |
| 2015-03-31 | $7.95M | $87.10M | $1.73M | $43.08M | (m) | 9.13% | 1.99% | (m) | (m) |
| 2014-12-31 | $8.14M | $105.59M | $1.61M | $61.45M | (m) | 7.71% | 1.52% | (m) | (m) |
| 2014-09-30 | $8.19M | $103.59M | $1.31M | $59.79M | (m) | 7.91% | 1.26% | (m) | (m) |
| 2014-06-30 | $7.81M | $99.29M | $1.29M | $57.27M | (m) | 7.86% | 1.29% | (m) | (m) |
| 2014-03-31 | $7.76M | $93.84M | $1.27M | $51.47M | (m) | 8.27% | 1.36% | (m) | (m) |
| 2013-12-31 | $7.06M | $75.08M | $1.27M | $32.61M | (m) | 9.40% | 1.69% | (m) | (m) |
| 2013-09-30 | $6.37M | $76.44M | $1.39M | $29.97M | (m) | 8.33% | 1.82% | (m) | (m) |
| 2013-06-30 | $5.97M | $73.45M | $1.31M | $24.93M | (m) | 8.13% | 1.78% | (m) | (m) |
| 2013-03-31 | $5.44M | $72.24M | $1.25M | $21.66M | (m) | 7.53% | 1.74% | (m) | (m) |
| 2012-12-31 | $5.39M | $71.36M | $1.15M | $19.72M | (m) | 7.55% | 1.61% | (m) | (m) |
| 2012-09-30 | $5.58M | $67.20M | $1.20M | $16.84M | (m) | 8.30% | 1.79% | (m) | (m) |
| 2012-06-30 | $5.89M | $70.89M | $1.24M | $18.93M | (m) | 8.31% | 1.75% | (m) | (m) |
| 2012-03-31 | $6.17M | $67.40M | $1.21M | $16.47M | (m) | 9.15% | 1.80% | (m) | (m) |
| 2011-12-31 | $6.17M | $64.78M | $1.19M | $13.97M | (m) | 9.52% | 1.84% | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $6.87M | $55.56M | $1.10M | $7.54M | (m) | 12.37% | 1.98% | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $8.18M | $40.14M | $958.02K | $5.59M | (m) | 20.38% | 2.39% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |